Fertility drug REKOVELLE® under the microscope in Real-World study

NCT ID NCT05499052

Completed Knowledge-focused Sponsor: Ferring Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observed 201 women in Nordic countries and Switzerland who were using the fertility drug REKOVELLE® for the first time during IVF or ICSI. Researchers tracked how doctors prescribed the drug, including dose adjustments and use of a dosing app, to understand real-world patterns. The goal was to gather information on effectiveness and safety without changing standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTROLLED OVARIAN STIMULATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTROLLED OVARIAN STIMULATION

Contacts and locations

Locations

Ferring Investigational Site

Copenhagen, Denmark
Ferring Investigational Site

Horsens, Denmark
Ferring Investigational Site

Køge, Denmark
Ferring Investigational Site

Odense, Denmark
Ferring Investigational Site

Søborg, Denmark
Ferring Investigational Site

Skien, Norway
Ferring Investigational Site

Malmö, Sweden
Ferring Investigational Site

Baden, Switzerland
Ferring Investigational Site

Basel, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.